Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.21.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
COSTS AND EXPENSES:    
Research and development $ 4,633,194 $ 2,616,337
General and administrative 1,726,338 1,342,318
Total costs and expenses 6,359,532 3,958,655
LOSS FROM OPERATIONS (6,359,532) (3,958,655)
OTHER INCOME:    
Interest income, net 2,362 1,047
Total other income, net 2,362 1,047
NET LOSS $ (6,357,170) $ (3,957,608)
BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (0.13) $ (0.42)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 48,139,189 9,389,661